← Back to Screener
TherapeuticsMD, Inc. (TXMD)
Price$2.19
Favorite Metrics
Price vs S&P 500 (26W)90.29%
Price vs S&P 500 (4W)-17.08%
Market Capitalization$25.35M
All Metrics
P/CF (Annual)34.63x
Book Value / Share (Quarterly)$2.37
P/TBV (Annual)0.43x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-11.84%
Cash Flow / Share (Quarterly)$0.18
Price vs S&P 500 (YTD)22.86%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)10.80%
EPS (TTM)$0.03
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$0.03
Revenue Growth (5Y)-48.72%
EPS (Annual)$-0.19
ROI (Annual)-7.97%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-1549.00%
Cash / Share (Quarterly)$0.61
P/E Basic Excl Extra (TTM)83.93x
Revenue Growth QoQ (YoY)43.33%
ROA (Last FY)-5.62%
Revenue Growth TTM (YoY)75.19%
EBITD / Share (TTM)$0.03
ROE (5Y Avg)-354.93%
Operating Margin (TTM)-98.25%
Cash Flow / Share (Annual)$0.06
P/B Ratio0.92x
P/B Ratio (Quarterly)0.45x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)6.52x
Net Interest Coverage (TTM)-5.42x
ROA (TTM)0.78%
EV / EBITDA (TTM)45.87x
EPS Incl Extra (Annual)$-0.19
Current Ratio (Annual)2.37x
Quick Ratio (Quarterly)2.43x
3-Month Avg Trading Volume0.07M
52-Week Price Return109.09%
EV / Free Cash Flow (Annual)24.91x
P/E Incl Extra (TTM)83.93x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$2.03
P/S Ratio (Annual)14.39x
Asset Turnover (Annual)0.05x
52-Week High$2.95
Operating Margin (5Y Avg)-851.90%
EPS Excl Extra (Annual)$-0.19
Tangible BV CAGR (5Y)-28.70%
26-Week Price Return99.04%
Quick Ratio (Annual)1.91x
13-Week Price Return-3.27%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.93x
Enterprise Value$18.233
Revenue / Share Growth (5Y)-56.73%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)-39.88%
Revenue / Employee (Annual)$2
Inventory Turnover (Annual)1.60x
Pretax Margin (Annual)-133.05%
Cash / Share (Annual)$0.44
3-Month Return Std Dev65.92%
Gross Margin (5Y Avg)81.23%
Net Income / Employee (TTM)$0
ROE (Last FY)-7.97%
Net Interest Coverage (Annual)-9.43x
EPS Basic Excl Extra (Annual)$-0.19
P/FCF (TTM)12.26x
Receivables Turnover (TTM)-1.85x
EV / Free Cash Flow (TTM)8.82x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.03
Receivables Turnover (Annual)2.28x
ROI (TTM)1.11%
P/S Ratio (TTM)9.07x
Pretax Margin (5Y Avg)-819.01%
Revenue / Share (Annual)$0.15
Tangible BV / Share (Annual)$2.00
Forward P/E12.94x
Price vs S&P 500 (52W)74.00%
P/E Ratio (TTM)83.93x
Year-to-Date Return26.99%
5-Day Price Return0.98%
EPS Normalized (Annual)$-0.19
ROA (5Y Avg)-21.67%
Net Profit Margin (Annual)-123.85%
Month-to-Date Return2.48%
Cash Flow / Share (TTM)$-3.86
EBITD / Share (Annual)$-0.17
Operating Margin (Annual)-270.30%
LT Debt / Equity (Annual)21.15x
P/CF (TTM)12.26x
ROI (5Y Avg)22.40%
P/E Excl Extra (TTM)83.93x
LT Debt / Equity (Quarterly)21.15x
EPS Basic Excl Extra (TTM)$0.03
P/TBV (Quarterly)0.53x
P/B Ratio (Annual)0.36x
Inventory Turnover (TTM)-1.60x
Pretax Margin (TTM)0.36%
Book Value / Share (Annual)$2.37
Price vs S&P 500 (13W)-6.14%
Beta0.63x
P/FCF (Annual)34.63x
Revenue / Share (TTM)$0.24
ROE (TTM)1.11%
52-Week Low$0.93
Analyst Recommendations
Nov 2023
Dec 2023
Jan 2024
Feb 2024
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TXMDTherapeuticsMD, Inc. | 9.07x | 75.19% | 100.00% | — | $2.19 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
TherapeuticsMD is a pharmaceutical royalty company that generates revenue from women's health products licensed to Mayne Pharma for U.S. commercialization, including IMVEXXY, BIJUVA, ANNOVERA, and prescription prenatal vitamins. By licensing its portfolio to an established pharmaceutical partner, the company collects royalties while minimizing operational expenses.